Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen

Naoe Goto; Hisashi Tsurumi; Masao Takemura; Takuro Matsumoto; Yuhei Shibata; Ryoko Mabuchi; Nobuhiko Nakamura; Hiroshi Nakamura; Tetsuya Yamada; Mitsuru Seishima; Tsuyoshi Takami; Tamotsu Takeuchi; Hisataka Moriwaki

首页> 外文期刊>Journal of clinical and experimental hematopathology : >Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen

【24h】

Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen

机译：血清可溶性肿瘤坏死因子受体1水平与CHOP或R-CHOP方案治疗的弥漫性大型B细胞淋巴瘤患者的预后相关

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of clinical and experimental hematopathology :》 |2014年第2期|共11页
作者
Naoe Goto; Hisashi Tsurumi; Masao Takemura; Takuro Matsumoto; Yuhei Shibata; Ryoko Mabuchi; Nobuhiko Nakamura; Hiroshi Nakamura; Tetsuya Yamada; Mitsuru Seishima; Tsuyoshi Takami; Tamotsu Takeuchi; Hisataka Moriwaki;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类产科学;
关键词

相似文献

外文文献
中文文献
专利

1. Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen [J] . Naoe Goto, Hisashi Tsurumi, Masao Takemura, Journal of clinical and experimental hematopathology : . 2014,第2期

机译：血清可溶性肿瘤坏死因子受体1水平与CHOP或R-CHOP方案治疗的弥漫性大型B细胞淋巴瘤患者的预后相关
2. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen [J] . Nakamura Nobuhiko, Goto Naoe, Tsurumi Hisashi, European Journal of Haematology . 2013,第4期

机译：可溶性肿瘤坏死因子受体2的血清水平与接受R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者的预后相关
3. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. [J] . Naoe Goto, Hisashi Tsurumi, Hideko Goto, Annals of hematology . 2012,第5期

机译：血清可溶性白介素2受体（sIL-2R）水平与接受R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者的预后相关。
4. Clinical significance and expression of microRNA-21 in diffuse large B-cell lymphoma cell lines and serum of patients [C] . CHEN Wei-qun, LU Honf-da, KONG De-yong, 2011 Asia-Pacific Conference of tumor biology and medicine . 2011

机译：患者弥漫性大B细胞淋巴瘤细胞株和血清中microRNA-21的表达及临床意义
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen [O] . Hussein M Khaled, Thoraya M Abdelhamid, Fouad M Abu-Taleb, 2019

机译：血清IL-18和可溶性IL-2受体水平对R-CHOP方案治疗弥漫性大B细胞淋巴瘤患者临床结局的影响
7. Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen [O] . Naoe Goto, Hisashi Tsurumi, Masao Takemura, 2014

机译：血清可溶性肿瘤坏死因子受体1水平与用剁碎或R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者的结果相关

Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen

著录项

相似文献

相关主题

期刊订阅